Medline's Old Story Already Broke - The Numbers Haven't

Medline (MDLN) fell roughly 14% premarket Wednesday after cutting full-year EBITDA guidance. The quarter itself - 11.6% sales growth, adjusted EBITDA up 13.4% to $1.06 billion - beat estimates. But the market heard what it wanted to hear: profit outlook trimmed from $3.5–$3.6 billion to $3.3 billion-$3.4 billion, and the selling started.

The tape reaction makes sense on the surface. The old story for Medline, since its late-2025 IPO, has been double-digit revenue growth colliding with margin pressure from tariffs, operating costs, and quality issues. The guidance cut looks like more of the same.

The problem is the operating engine underneath the headline has flipped. The first-half numbers, the free cash flow, and the customer pipeline don't look like a company in structural margin trouble. They look like a business that's already pulling away from its IPO-year problems while the market is still sitting on the old script.

The old story: margin compression

Going public in 2025, Medline inherited the narrative of a high-growth med-surg distributor eating its own margins. Full-year 2025 net income fell 3.6% to $1.2 billion despite 11.5% sales growth. Adjusted EBITDA - earnings before interest, taxes, depreciation, and amortization, a proxy for operating cash generation - grew only 3.2% to $3.5 billion. The spread between top-line acceleration and bottom-line lag was the whole trade.

Tariffs, cost of goods sold, and higher operating expenses were the cited headwinds. In Q1 2026, those same pressures showed up again: adjusted EBITDA fell 10.6% to $776 million. The market had every reason to believe Medline was growing its way into a profitability wall.

What the Q2 numbers actually show

Q2 tells a different story. Adjusted EBITDA rose 13.4% year-over-year to $1.06 billion. Organic sales grew 11.5%. Supply Chain Solutions - the segment that locks in hospital relationships and converts them to higher-margin Medline-brand products - grew 16%. U.S. acute care was up 15%. New customer signings topped $650 million in the first half, ahead of the $1 billion annual goal.

The full-year organic sales outlook was raised to 9–10%, up from 8.5–9.5%. Management didn't lose confidence in demand. They're more confident than they were in May.

The EBITDA guidance cut is real, but the drivers matter. The Tracy, California distribution-center fire - a 1-million-square-foot facility that burned in 30 to 40 minutes on June 11 - reduced first-half net income by $336 million. Another $50 million to $100 million of fire-related costs are expected in the second half. Quality remediation on convenience kits (more than 970 lots recalled in July after a potential sterility breach) and delayed product reintroductions are also weighing on the outlook. And a $243 million net benefit from IEEPA tariff refunds in Q2 won't repeat.

Strip out the one-time Q2 tariff benefit and the run-rate picture softens, but it doesn't break. The structural drivers - customer signings ahead of pace, double-digit organic growth across segments, supply chain solutions scaling - are accelerating, not decelerating.

Free cash flow is the anchor

The headline that didn't move the tape: $920 million of free cash flow in the first six months. For context, all of 2025 generated $1.3 billion. Medline is on pace to exceed last year's full-year free cash flow before the second half is halfway done.

Net leverage - total debt minus cash, divided by EBITDA - dropped to 2.9 times, already below the company's long-term target of 3.0 times. That number was 4.9 times before the IPO. The deleveraging is not aspirational; it's done.

Free cash flow of this magnitude, on a revenue base growing at double digits, is the kind of proof point that makes margin debates academic. You can argue about quarterly EBITDA noise when the cash machine is printing $920 million in six months.

Why the market is still pricing the old story

AInvest's aggregate signal still labels the stock a Buy, and the composite analysis rating sits at 4.02 out of 5. But the premarket selloff tells a different story. Investors are reacting to the guidance cut, not digesting the cash flow or customer momentum.

There are mechanical reasons for the disconnect. Blackstone, Hellman & Friedman, Carlyle, and the Abu Dhabi Investment Authority have been selling through secondary offerings since the IPO - 86.25 million shares in March, another 72.55 million in May. That persistent overhang makes it easy for the market to treat Medline as a private-equity exit story rather than an operating company. The secondary selling is real headwind, but it doesn't change the fact that the business itself is generating cash faster than debt is being repaid.

Forward, the stock sits around 28 times next year's earnings. That's not cheap, but it's also not a company being rewarded for $920 million of annualized free cash flow, sub-3.0x leverage, and a customer pipeline that's ahead of pace.

The bridge and the tripwire

Here's the setup over the next 12 months. The Tracy fire rebuild and California distribution expansion are capital-intensive but structural investments that management expects to improve supply-chain resilience. The tariff refund normalization in Q2 was a bump, not a structural decline. Quality remediation is a fixable operational issue, not a business model failure - though it needs to stay that way.

If H2 EBITDA normalizes as the fire costs are fully recognized and quality issues resolve, the $3.3–$3.4 billion full-year guidance looks like a floor, not a ceiling. First-half EBITDA was roughly $1.84 billion ($776 million in Q1 plus $1.06 billion in Q2). H2 needs roughly $1.46–$1.56 billion to hit the low end of the new guidance, or about $730–$780 million per quarter. That's well below Q2's actual result, even after removing the tariff refund.

The inflection thesis rests on three things: - Customer momentum holds. $650 million in H1 signings needs to continue at a similar clip. - Quality issues resolve without recurring. The CHG wipes and convenience kit recalls need to be a one-off remediation, not a pattern. - Free cash flow stays above $1 billion annualized. The $920 million H1 number needs to hold.

If those hold, a forward multiple in the 30–32x range on next year's EPS of roughly $1.60 implies a $48–$51 range over the next 12 to 18 months. That's a simple forward-multiple bridge, not a DCF. The business is generating cash, growing revenue, and deleveraging. Simple math beats complex models.

The tripwire is clear: if Q3 EBITDA falls below $800 million on a run-rate basis, or if quality issues surface again in a new product line, the operating acceleration thesis is in trouble. If free cash flow for the full year ends below $1.5 billion, the cash-generation story loses its edge. Cut the position if either fires - discipline over ego.

What could still go wrong

Three real risks. Tariffs are structural, not cyclical - the trade environment isn't reverting to pre-2025 norms, and Medline's cost of goods sold will carry that weight. Quality issues in a medical-supply business are reputational, not just financial; another recall could pressure customer retention in a way that's harder to quantify. And the secondary offering overhang doesn't disappear on a timeline - selling shareholders still have inventory to work through.

None of these change the fact that the operating engine is stronger than the market's pricing suggests. But they do mean the setup isn't risk-free.

The selloff matters less than the fact that expectations have already reset while the numbers have not broken. The market is still pricing the margin-compression story. The free cash flow and customer momentum say otherwise. When the second-half results confirm that the guidance cut was event-driven rather than structural, the rerating path opens up. If they don't, the thesis is easy to prove wrong.

That's the difference between a broken business and a temporarily noisy one. Medline's first-half cash generation puts it firmly in the latter camp - for now.